ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date ...

Droperidol was a first-line, highly effective agent for the treatment of PONV for over 30 years. It has the most postmarketing surveillance data of any of the currently used antiemetic agents.